“…The sarcomatous component may be homologous (endometrial stromal sarcoma, fibrosarcoma or leiomyosarcoma) or heterologous (rhabdomyosarcoma, chondrosarcoma, osteosarcoma or liposarcoma) [1,2,3]. The patients' overall survival is still unsatisfactory due to the high rate of distant recurrences [2,4,5,6,7,8,9]. In general, the overall 5-year survival for all clinical stages of uterine CSs is nearly 30%, increasing to 50% for tumors confirmed only to the uterus [4,6,10,11].…”